Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation

Exclusion Criteria

• •1. Subject has ever been treated for prostate cancer with any of the following:
• •* Radiotherapy (external beam or brachytherapy)
• •* Chemotherapy
• •* Hormonal therapy (e.g., megestrol, medroxyprogesterone, cyproterone, diethyl-stilbestrol (DES)
• •* Oral glucocorticoids
• •* Gonadotropin Releasing Hormone (GnRH) analogues (e.g., leuprolide, goserelin) other than the single-dose gosereline given as treatment in this study.
• •2. Glucocorticoids, except inhaled or topical, are not permitted within 3 months prior to visit one
• •3. Current and/or previous use of the following medications:
• •* Finasteride (Proscar, Propecia), or Dutasteride (Avodart) exposure within 6 months prior to study entry are excluded.
• •* Any other investigational 5-reductase inhibitors within the past 12 months.
• •* Anabolic steroids (subject must discontinued for 6 months prior to study entry to be eligible)
• •* Drugs with antiandrogenic properties within the past 6 months (e.g,. spironolactone, flutamide, bicalutamide, \*cimetidine, \*ketoconazole, progestational agents) \*The use of cimetidine is permitted prior to study entry. The use of topical ketoconazole is permitted prior to and during the study.